KR101014317B1 - Weissella cibaria 148-2 lactic bacteria for functional healthy effect and Makgeolli containing the same - Google Patents
Weissella cibaria 148-2 lactic bacteria for functional healthy effect and Makgeolli containing the same Download PDFInfo
- Publication number
- KR101014317B1 KR101014317B1 KR1020080133488A KR20080133488A KR101014317B1 KR 101014317 B1 KR101014317 B1 KR 101014317B1 KR 1020080133488 A KR1020080133488 A KR 1020080133488A KR 20080133488 A KR20080133488 A KR 20080133488A KR 101014317 B1 KR101014317 B1 KR 101014317B1
- Authority
- KR
- South Korea
- Prior art keywords
- activity
- strain
- makgeolli
- strains
- health functional
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title claims description 33
- 230000000694 effects Effects 0.000 title description 30
- 241000975185 Weissella cibaria Species 0.000 title description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 50
- 239000004310 lactic acid Substances 0.000 claims abstract description 25
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 25
- 230000036541 health Effects 0.000 claims abstract description 24
- 230000005714 functional activity Effects 0.000 claims abstract description 20
- 230000001093 anti-cancer Effects 0.000 claims abstract description 19
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 16
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 15
- 230000005965 immune activity Effects 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims description 7
- 235000014101 wine Nutrition 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 10
- 230000010261 cell growth Effects 0.000 abstract description 8
- 235000019991 rice wine Nutrition 0.000 abstract description 8
- 241000866751 Sibaria Species 0.000 abstract description 7
- 241000202221 Weissella Species 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 23
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 description 12
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 230000009036 growth inhibition Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000209094 Oryza Species 0.000 description 8
- 235000007164 Oryza sativa Nutrition 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 235000009566 rice Nutrition 0.000 description 8
- 238000005259 measurement Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000004382 Amylase Substances 0.000 description 6
- 102000013142 Amylases Human genes 0.000 description 6
- 108010065511 Amylases Proteins 0.000 description 6
- 235000019418 amylase Nutrition 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 102000016938 Catalase Human genes 0.000 description 5
- 108010053835 Catalase Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 231100000002 MTT assay Toxicity 0.000 description 4
- 238000000134 MTT assay Methods 0.000 description 4
- 102000004316 Oxidoreductases Human genes 0.000 description 4
- 108090000854 Oxidoreductases Proteins 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000192001 Pediococcus Species 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 238000003794 Gram staining Methods 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000001967 plate count agar Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 235000005135 Micromeria juliana Nutrition 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 240000002114 Satureja hortensis Species 0.000 description 1
- 235000007315 Satureja hortensis Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194018 Streptococcaceae Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000019997 soju Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
- C12G3/00—Preparation of other alcoholic beverages
- C12G3/04—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs
- C12G3/05—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs with health-improving ingredients, e.g. flavonoids, flavones, polyphenols or polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Abstract
본 발명은 건강기능활성을 가지는 와이셀라 시바리아(Weisella cibaria) 148-2 균주 및 이를 포함하는 막걸리에 관한 것으로, 보다 상세하게는 막걸리로부터 분리된 항암활성, 면역활성, 항염증활성 및 항산화활성의 건강기능활성을 가지는 와이셀라 시바리아 148-2 균주 및 상기의 건강기능활성을 가지는 와이셀라 시바리아 148-2 균주를 포함하는 기능성 막걸리에 관한 것이다.The present invention relates to Weisella cibaria 148-2 strain having health functional activity and makgeolli comprising the same, and more particularly, to anticancer activity, immune activity, anti-inflammatory activity and antioxidant activity isolated from makgeolli. Waisella Sibaria with health functional activity It relates to a functional makgeolli comprising 148-2 strain and the Weissella sibaria 148-2 strain having the above health functional activity.
본 발명의 막걸리로부터 분리된 젖산균주는 항암활성 등의 효능을 가지는 기능성 발효주의 접종균주가 될 수 있으며, 이 균주를 포함시켜 제조된 막걸리는 상기의 효능을 가지는 발효주로서 일반 수요자에게 건강기능식 전통주로써 제공되어 질 수 있다.Lactic acid strain isolated from the Makgeolli of the present invention can be inoculated strains of functional fermented strains having efficacy such as anti-cancer activity, Makgeolli prepared by including this strain as fermented strains having the above-mentioned efficacy as a health functional traditional liquor to the general consumer Can be provided.
와이셀라 시바리아(Weisella cibaria) 148-2 균주, 항암활성, 면역활성, 항염증활성, 항산화활성, 세포 생장억제율, 막걸리 Weisella cibaria 148-2 strain, anticancer activity, immune activity, anti-inflammatory activity, antioxidant activity, cell growth inhibition rate, rice wine
Description
본 발명은 건강기능활성을 가지는 와이셀라 시바리아(Weisella cibaria) 148-2 균주 및 이를 포함하는 막걸리에 관한 것으로, 보다 상세하게는 막걸리로부터 분리된 항암활성, 면역활성, 항염증활성 및 항산화활성의 건강기능활성을 가지는 와이셀라 시바리아 148-2 균주 및 상기의 건강기능활성을 가지는 와이셀라 시바리아 148-2 균주를 포함하는 기능성 막걸리에 관한 것이다.The present invention relates to Weisella cibaria 148-2 strain having health functional activity and makgeolli comprising the same, and more particularly, to anticancer activity, immune activity, anti-inflammatory activity and antioxidant activity isolated from makgeolli. Waisella Sibaria with health functional activity It relates to a functional makgeolli comprising 148-2 strain and the Weissella sibaria 148-2 strain having the above health functional activity.
막걸리는 찹쌀·멥쌀·보리·밀가루 등을 쪄서 누룩과 물을 섞어 발효시킨 한국 고유의 술로, 원료는 곡류이며 분류는 약주에 포함되고 알콜농도는 보통 6~7도 정도가 되는 전통주이다. 막걸리는 탁주(濁酒)·농주(農酒)·재주(滓酒)·회주(灰酒)라고도 한다. 한국에서 역사가 가장 오래된 술로, 빛깔이 뜨물처럼 희고 탁하며, 6∼7도로 알코올 성분이 적은 술이다.Makgeolli is a Korean liquor made by mixing glutinous rice, non-glutinous rice, barley, and wheat flour with fermented malt. Makgeolli is also known as Takju (주 酒), Nongju (農 酒), Soju (회 酒), and Hoeju (灰 酒). It is the oldest alcoholic beverage in Korea. The color is white and turbid like hot water, and the alcohol content is 6-7 degrees.
막걸리는 각 지방의 관인(官認) 양조장에서만 생산되고 있는데, 예전에 농가에서 개별적으로 제조한 것을 농주라 한다. 고려시대부터 알려진 대표적인 막걸리로 이화주(梨花酒)가 있는데, 가장 소박하게 만드는 막걸리용 누룩은 배꽃이 필 무렵에 만든다 하여 그렇게 불렀으나, 후세에 와서는 아무때에나 만들게 되었고, 이화주란 이름도 점점 사라졌다. 중국에서 전래된 막걸리는 《조선양조사》에 “처음으로 대동강(大同江) 일대에서 빚기 시작해서, 국토의 구석구석까지 전파되어 민족의 고유주(固有酒)가 되었다”라고 씌어 있는데, 진위를 가리기는 어렵다.Makgeolli is produced only at local Gwan-in breweries. In the past, rice wine was produced individually by farmers. The representative Makgeolli known from the Goryeo Dynasty is Ihwaju (梨花 酒). The simplest makgeolli for yeast was called pear flower when it was made, but it was made at any time in later generations. lost. Makgeolli, which was introduced in China, is written in the Survey of Korean Oceans, which first began to be formed around the Daedong River and spread to every corner of the country to become a national indigenous liquor. It is difficult to hide.
제조방법은 주로 찹쌀·멥쌀·보리·밀가루 등을 찐 다음 수분을 건조시켜(이것을 지에밥이라고 한다) 누룩과 물을 섞고 일정한 온도에서 발효시킨 것을 청주를 떠내지 않고 그대로 걸러 짜낸다. 옛날 일반 가정에서는 지에밥에 누룩을 섞어 빚은 술을 오지그릇 위에‘井’자 모양의 겅그레를 걸고 그 위에 올려놓고 체에 부어 거르면 뿌옇고 텁텁한 탁주가 되는데 이것을 용수를 박아서 떠내면 맑은술[淸酒]이 된다. 이때 찹쌀을 원료로 한 것을 찹쌀막걸리, 거르지 않고 그대로 밥풀이 담긴 채 뜬 것을 동동주라고 한다. 좋은 막걸리는 단맛·신맛·쓴맛·떫은맛이 잘 어울리고 감칠맛과 시원한 맛이 있는 것으로서, 땀 흘리고 일한 농부들의 갈증을 덜어주어 농주로서 애용되어 왔다.The manufacturing method is mainly steamed glutinous rice, non-glutinous rice, barley, flour, etc., and then dried moisture (this is called jiebab). The yeast and water are mixed and fermented at a constant temperature. In the old homes, the liquor made by mixing yeast with Jiebab is placed on a crock bowl, put on '井' shaped rice, put it on a sieve, and poured into a sieve. ]. At this time, glutinous rice Makgeolli, which is made from glutinous rice, is mixed with rice paste without being filtered. Good makgeolli is a sweet, sour, bitter and astringent taste that is well suited and has a savory and cool taste. It has been used as a farmer by relieving the thirst of farmers who sweat and work.
막걸리는 곡물을 이용해 누룩과 효모로 발효시킨 전통주로 일반 술에 비해 영양성분이 많이 함유되어 있을 뿐만 아니라 갑작스런 혈당의 감소현상을 막아주기도 하며 위와 간에 부담을 주지 않는 것으로 알려져 있다. 막걸리의 제조 과정은 누룩 미생물 중 곰팡이의 아밀라아제에 의한 쌀전분의 당화 공정과 발효성 당의 알 콜로의 전환 과정(발효공정) 등 두 가지 공정을 여러 미생물의 제 효소 반응의 조화에 의해 병행 복 발효를 거친다. 시판되고 있는 막걸리의 경우 제조된 곡자 및 입국을 쓰는 경우가 많이 있으며 이들의 제조 과정에 누룩이나 효모뿐만 아니라 젖산균, 박테리아와 같은 여러 미생물들이 첨가되기도 한다. 대부분의 경우 막걸리의 품질은 곰팡이와 누룩에 의해 많은 부분 결정이 되나 젖산균과 박테리아가 큰 영향을 미치기도 한다.Makgeolli is a traditional liquor fermented with yeast and yeast using grains. It contains more nutrients than regular alcohol and prevents sudden blood sugar reduction and does not burden the stomach and liver. The manufacturing process of makgeolli consists of two processes: the saccharification process of rice starch by fungal amylase and the fermentative sugar conversion of alcohol into fermentation process (fermentation process). Rough In the case of commercially available makgeolli, there are many cases of using manufactured grain and immigration, and many microorganisms such as lactic acid bacteria and bacteria are added to their manufacturing process as well as yeast and yeast. In most cases, the quality of makgeolli is largely determined by mold and yeast, but also by lactic acid bacteria and bacteria.
글루코오스 등 당류를 분해하여 젖산을 생성하는 세균으로 유산균이라고도 한다. 젖산발효에 의해 생성되는 젖산에 의해서 병원균과 유해세균의 생육이 저지되는 성질을 유제품·김치류·양조식품 등의 식품제조에 이용한다. 또, 포유류의 장내에 서식하여 잡균에 의한 이상발효를 방지하여 정장제(整腸劑)로도 이용되는 중요한 세균이다. 그람양성균이며, 통성혐기성 또는 혐기성이다. 락토바실루스속과 스트렙토코쿠스속에 여러 종류가 알려져 있다. A bacterium that breaks down sugars such as glucose to produce lactic acid, also known as lactic acid bacteria. The lactic acid produced by lactic acid fermentation prevents the growth of pathogens and harmful bacteria in food production such as dairy products, kimchi and brewed foods. In addition, it is an important bacterium that lives in the intestine of mammals and prevents abnormal fermentation by various bacteria, and is also used as a formal drug. It is a gram-positive bacterium and is anaerobic or anaerobic. There are several known species in the genus Lactobacillus and Streptococcus.
젖산균은 락트산균·유산균이라고도 한다. 젖산발효에 의해 생성되는 젖산에 의해서 병원균과 유해세균의 생육이 저지되는 성질을 유제품(乳製品:요구르트·치즈 등)·김치류·양조식품(청주·된장·간장 등) 등의 식품제조에 이용한다. 또, 포유류의 장내에 서식하여 잡균에 의한 이상발효를 방지하여 정장제(整腸劑)로도 이용되는 중요한 세균이다. 그람양성균이며, 통성혐기성 또는 혐기성이다. 운동성은 없고 대부분이 카탈라아제 음성이고, 생육에는 각종 비타민, 아미노산, 어떤 종류의 펩티드 등을 요구한다. Lactic acid bacteria are also called lactic acid bacteria and lactic acid bacteria. The lactic acid produced by lactic acid fermentation prevents the growth of pathogens and harmful bacteria, and is used in the production of foods such as dairy products (yogurt, cheese, etc.), kimchi, brewed foods (cheongju, miso, soy sauce, etc.). In addition, it is an important bacterium that lives in the intestine of mammals and prevents abnormal fermentation by various bacteria, and is also used as a formal drug. It is a gram-positive bacterium and is anaerobic or anaerobic. There is no mobility and most are catalase negative, and growth requires various vitamins, amino acids, certain types of peptides, and the like.
젖산균은 미생물 분류학상으로는 유박테리알레스목(Eubacteriales)에 포함된 다. 이 과는 락토바실레아에족(Lactobacilleae)과 스트렙토코카세아에족(Streptococcaceae)으로 구분되는데, 전자에서는 락토바실루스속(Lactobacillus)이, 후자에서는 스트렙토코쿠스속(Streptococcus)·페디오코쿠스속(Pediococcus)·류코노스톡속(Leuconostoc)이 중요하다. 형태학상으로는 젖산 간균(桿菌:락토바실루스속)과 젖산 구균(球菌:스트렙토코쿠스속·페디오코쿠스속·류코노스톡속)으로 대별되고, 생리학적으로는 당을 혐기적으로 분해하여 주로 젖산만을 생성하는 호모발효균과, 젖산 외에 부산물(알코올·이산화탄소 등)을 생성하는 헤테로발효균으로 분류된다. 또, 생성된 젖산의 광회전성 등에 의해서도 나누어진다. Lactic acid bacteria are included in Eubacteriales by microbial taxonomy. The family is divided into Lactobacilleae and Streptococcaceae, in the former Lactobacillus genus and in the latter Streptococcus and Pediococcus genus Pediococcus. Leuconostoc is important. In terms of morphology, it is classified into Lactic Acid Bacillus (Lactobacillus) and Lactic Acid Bacteria (Streptococcus, Pediococcus, and Leukonostock). It is classified into homo-fermenting bacteria to be produced and hetero-fermenting bacteria which produce by-products (alcohol, carbon dioxide, etc.) in addition to lactic acid. It is also divided by the light rotational properties of the produced lactic acid.
젖산균을 이용한 막걸리 등의 전통주 제조방법에 대하여 많은 연구와 실험이 수행되고 오고 있다. 몸에 유용한 기능(항암, 면역작용, 항염증 등)을 하는 신 젖산균의 개발과 이용이 요구된다. 이를 통하여 우리의 전통주인 막걸리를 세계화 시킬 수도 있을 것으로 기대된다. Many researches and experiments have been carried out on the manufacturing method of traditional liquor such as makgeolli using lactic acid bacteria. The development and use of renal lactic acid bacteria that function useful to the body (anticancer, immune action, anti-inflammatory, etc.) is required. It is expected that this will make our traditional liquor rice wine global.
본 발명의 목적은 건강기능활성을 가지는 신균주의 탐색과 분리를 통하여 발효주에 이용 가능한 기능적 균주를 제공하고자 함이며, 상기 균주를 이용하여 항암활성 등의 효능을 가지는 전통주를 제공하고자 한다.An object of the present invention is to provide a functional strain that can be used in fermented strains through the search and separation of new strains having health functional activity, to provide a traditional strain having the efficacy, such as anticancer activity using the strain.
상기의 과제를 해결하고자,To solve the above problems,
본 발명은 막걸리로부터 분리된 항암활성, 면역활성, 항염증활성 및 항산화활성의 건강기능활성을 가지는 와이셀라 시바리아(Weisella cibaria) 148-2 균주를 제공한다.The present invention is Weisella cibaria having a health functional activity of anticancer activity, immune activity, anti-inflammatory activity and antioxidant activity isolated from makgeolli 148-2 strain is provided.
또한 본 발명은 상기의 건강기능활성을 가지는 와이셀라 시바리아(Weisella cibaria) 148-2 균주를 포함하는 막걸리를 제공한다.In another aspect, the present invention is Weisella cibaria having the above health functional activity ( Weisella cibaria ) Makgeolli comprising 148-2 strain is provided.
본 발명의 막걸리로부터 분리된 젖산균주는 항암활성 등의 효능을 가지는 기능성 발효주의 접종균주가 될 수 있으며, 이 균주를 포함시켜 제조된 막걸리는 상기의 효능을 가지는 발효주로서 일반 수요자에게 건강기능식 전통주로써 제공되어 질 수 있다.Lactic acid strain isolated from the Makgeolli of the present invention can be inoculated strains of functional fermented strains having efficacy such as anti-cancer activity, Makgeolli prepared by including this strain as fermented strains having the above-mentioned efficacy as a health functional traditional liquor to the general consumer Can be provided.
본 발명은 건강기능활성을 가지는 와이셀라 시바리아(Weisella cibaria) 148-2 (KACC 91421P)균주를 제공한다.The present invention Weisella cibaria having a health functional activity 148-2 (KACC 91421P) strain is provided.
본 발명에서 상기 균주는 항암활성, 면역활성, 항염증활성 및 항산화활성의 건강기능활성을 가지는 것을 특징으로 한다.In the present invention, the strain is characterized by having a health functional activity of anticancer activity, immune activity, anti-inflammatory activity and antioxidant activity.
또한 본 발명에서 상기 균주는 막걸리에서 분리된 젖산균임을 특징으로 한다.In the present invention, the strain is characterized in that the lactic acid bacteria isolated from makgeolli.
본 발명은 상기의 건강기능활성을 가지는 와이셀라 시바리아(Weisella cibaria) 148-2 균주를 포함하는 막걸리를 제공한다.The present invention is Weisella cibaria having the above health functional activity ( Weisella cibaria ) Makgeolli comprising 148-2 strain is provided.
본 발명의 막걸리에서, 상기 균주는 항암활성, 면역활성, 항염증활성 및 항산화활성의 건강기능활성을 가지는 것을 특징으로 한다.In the rice wine of the present invention, the strain is characterized by having a health functional activity of anticancer activity, immune activity, anti-inflammatory activity and antioxidant activity.
이하 본 발명의 건강기능활성을 가지는 와이셀라 시바리아(Weisella cibaria) 148-2 균주 및 이를 포함하는 막걸리에 대하여 실시예 및 실험예를 통하여 상세하게 설명한다.Hereinafter, Weisella cibaria having health functional activity of the present invention 148-2 strains and makgeolli containing the same will be described in detail with reference to Examples and Experimental Examples.
본 발명은 막걸리로부터 젖산균의 일종으로 추정되는 미생물을 탐색하고, 탐색된 미생물을 이용한 발효주에 관한 것이다. 본 발명에서는 상기 탐색하여 분리된 균주의 항암활성, 면역활성, 항염증활성 등을 통하여 목적으로 하는 기능을 가지는 균주를 선별하고, 선별된 균주를 가지고 세포 생장억제율 측정, QR(Quinone reductase) 활성 측정 및 항산화활성을 측정하였다.The present invention relates to a fermented liquor using the microorganisms searched for microorganisms estimated to be a kind of lactic acid bacteria from rice wine. In the present invention, by selecting the strain having the desired function through the anticancer activity, immune activity, anti-inflammatory activity and the like of the isolated strain, and measuring the cell growth inhibition rate, QR (Quinone reductase) activity with the selected strain And antioxidant activity was measured.
또한 상기의 선별된 균주를 포함하는 막걸리에 대한 세포 생장억제율에 대한 실험을 통하여 본 발명의 효능을 증명하였다.In addition, the efficacy of the present invention was demonstrated through experiments on cell growth inhibition rate for makgeolli containing the selected strains.
<실시예> 균주의 분리EXAMPLES Isolation of Strains
1. 균주의 분리 과정 1. Isolation Process of Strains
본 실시예에서는 시판 막걸리와 실험실내에서 담근 막걸리에서 미생물들을 분리하였고, 이들이 가지는 건강기능활성을 측정하여 우수한 균주를 선발하고자 하였다. 단백질 가수분해효소 (protease), 아밀라아제 (amylase) 활성과 다당류 생성이 우수한 균주를 우선적으로 선발하였고, 선발 균주들의 간이동정을 통해 젖산균 가능성을 타진하였다. In this example, the microorganisms were isolated from commercial makgeolli and dipped makgeolli in the laboratory, and the excellent strains were selected by measuring their health functional activity. Strains with superior protease, amylase activity and polysaccharide production were selected first, and the possibility of lactic acid bacteria was identified through the liver identification of the selected strains.
Protease, amylase 활성과 다당류 생성이 우수한 균주의 선발을 위하여 시중에서 수집한 막걸리 30개와 한국식품연구원 보유 누룩으로 제조한 막걸리 114개를 peptone dilution fluid를 이용하여 10배 희석법으로 희석하였고, protease 활성을 보기 위한 배지 (Plate count agar에 2%의 skim milk를 첨가한 것), 다당체 혈성을 보기 위한 배지 (Plate count agar에 10%의 sucrose를 첨가한 것) 그리고 amylase 활성을 보기 위한 배지 (0.05% congo red, 0.5% starch, 0.1% yeast nitrogen, 1.5% agar를 첨가한 것)와 같은 세 가지 배지를 이용하여 활성이 높은 균을 분리하였다. For the selection of strains with excellent protease, amylase activity and polysaccharide production, 30 makgeollis collected in the market and 114 makgeollis made from Nuruk possessed by Korea Food Research Institute were diluted by 10-fold dilution method using peptone dilution fluid. Medium for 2% skim milk added to plate count agar, medium for 10% sucrose addition to plate count agar, and medium for amylase activity (0.05% congo red) , 3% of 0.5% starch, 0.1% yeast nitrogen and 1.5% agar) were used to isolate highly active bacteria.
2. 균주의 분리 결과2. Isolation Result of Strains
상기 1.과정을 통하여 분리된 균주를 광학 현미경에 의한 세포관찰, Gram staining, catalase test 그리고 oxidase test를 이용하여 미생물 간의 동정을 수행하였다. 그 결과 144개의 시료에서 총 265개의 미생물이 분리되었으며, 이들 265 미생물 중 상대적으로 단백질분해, 전분분해 활성 그리고 다당체 형성이 높은 균주, 그리고 미생물 간이동정을 통하여 젖산균으로 추정되는 균주 (Gram staining 양성, oxidase test 음성, catalase test 음성)를 선발한 결과는 아래 표 1 및 2에서 보여주는 것과 같다. 시판 막걸리에서 3개, 누룩을 이용해 담은 막걸리에서 17개 총 20개의 균주가 1차로 선발되었다 (이하 표 1 및 2 참조).The strain isolated through the above 1. process was identified between microorganisms using cell observation by optical microscope, Gram staining, catalase test and oxidase test. As a result, a total of 265 microorganisms were isolated from 144 samples, and among these 265 microorganisms, strains with relatively high proteolytic, starch-degrading activity and polysaccharide formation, and strains estimated to be lactic acid bacteria through microbial liver identification (Gram staining positive, oxidase) test negative, catalase test negative) results are shown in Tables 1 and 2 below. A total of 17 strains of 17 strains were selected first from commercial makgeolli, and from makgeolli containing yeast (see Tables 1 and 2 below).
[표 1] 시판 막걸리에서 분리된 균주의 1차 실험 결과Table 1 First Experimental Results of Strains Isolated from Commercial Makgeolli
번호Strain
number
testCatalase
test
분해능protease
Resolution
형성능slime
Formation ability
활성Amylase
activation
(상기 표 1에서 ' ++: 활성 큼, + : 활성 있음, - : 활성 없음, () : 활성이 나타나기는 하나 정도가 희미함 ' 을 의미한다. )(In Table 1, it means '++: greater activity, +: active,-: no activity, (): one degree of activity appears faint').)
[표 2] 실험실내에서 누룩을 이용하여 담근 막걸리에서 분리한 균주의 1차 실험결과Table 2 First Experimental Results of Strains Isolated from Makgeolli Dipped Using Nuruk in the Laboratory
번호Strain
number
testCatalase
test
분해능protease
Resolution
형성능slime
Formation ability
활성Amylase
activation
(상기 표 2에서 ' ++: 활성 큼, + : 활성 있음, - : 활성 없음, () : 활성이 나타나기는 하나 정도가 희미함 ' 을 의미한다. )(In Table 2, it means '++: greater activity, +: active,-: no activity, (): one degree of activity appears faint').)
<실험예 1> 항암활성 효과에 관한 실험Experimental Example 1 Experiment on Anticancer Activity Effect
1. 항암활성 효과의 측정방법1.Measurement of anticancer activity effect
상기 실시예에 의하여 1차로 선발된 20개의 선발균주를 이용하여 먼저 항암 효과를 관찰하기 위하여 MTT assay를 수행하였다. MTT assay was performed first to observe the anticancer effect using 20 selection strains selected first by the above examples.
MTT assay를 실시하기 위해서 우선 균주를 MRS agar 배지를 이용해 24시간 동안 배양하였고, 다 자란 미생물은 PBS를 이용하여 희석시킨다음 autoclave를 이용해 균을 사멸시킨 후 시료로 이용하였다. In order to perform the MTT assay, the strains were first incubated for 24 hours using MRS agar medium, and the grown microorganisms were diluted with PBS and then killed with bacteria using autoclave.
MTT assay는 정상세포주인 CHO-K1와 대장암 세포주인 SNU-C4를 이용해 준비된 균 시료를 10% 농도로 투여한 다음 72 시간 동안 배양하였고, 배양 후 MTT 시약 을 처리하여 세포 생장 억제율을 측정하였다.In the MTT assay, 10% concentrations of the bacterial samples prepared using the normal cell line CHO-K1 and the colorectal cancer cell line SNU-C4 were administered, followed by incubation for 72 hours. After the incubation, treatment with MTT reagent was used to measure cell growth inhibition rate.
2. 항암활성 효과 측정결과2. Results of Anticancer Activity
암세포주인 SNU-C4와 정상세포주인 CHO-K1의 생장 억제율을 비교하여 상대적으로 정상세포주인 CHO-K1의 생장 억제율이 낮은값을 가진 동시에 암세포 SNU-C4의 생장 억제율이 높은 균을 항암활성 우수균주로 판정하였다. 세 번에 걸친 실험 결과 148-2 균주가 가장 항암활성 효과가 좋은 균주로 밝혀졌으며, 이외에도 148-1, 284-2, 197-4 균주가 효과가 좋은 것으로 나타났다(이하 표 3 참조). By comparing the growth inhibition rate of cancer cell line SNU-C4 with normal cell line CHO-K1, the strains with relatively low growth inhibition rate of normal cell line CHO-K1 and high growth inhibition rate of cancer cell SNU-C4 were selected. Was determined. As a result of three experiments, 148-2 strains were found to have the best anticancer activity, and 148-1, 284-2, and 197-4 strains were also effective (see Table 3 below).
[표 3] 균주를 처리한 정상 세포주와 대장암 세포주에서의 생장 억제율(세포 억제율은 % 농도로 나타냄)TABLE 3 Growth inhibition rate in normal cell line and colon cancer cell line treated with strain (cell inhibition rate is expressed as% concentration)
<실험예 2> 면역활성 효과에 관한 실험Experimental Example 2 Experiment on Immune Activity Effect
1. 면역활성 효과의 측정방법1.Measurement of immune activity effect
상기 실시예에 의하여 1차로 선발된 균주의 면역활성을 측정하기 위하여 면역증강 물질 중의 하나인 NO (nitric oxide)를 측정하였다. 선발균주의 면역활성 측정은 대식세포인 RAW 264.7 세포주에 균주시료 10% 희석액을 처리하고 20시간 동안 배양시킨 다음, Griess 시약을 이용해 배지내에 생성된 NO의 양을 측정 하였다. In order to measure the immune activity of the strain first selected by the above example, nitric oxide (NO), which is one of the immune enhancing substances, was measured. To measure the immune activity of the selected strains, 10% dilution of the strain sample in RAW 264.7 cell line, which is a macrophage, was incubated for 20 hours, and then the amount of NO generated in the medium was measured using Griess reagent.
2. 면역활성 효과의 측정결과2. Measurement result of immune activity effect
면역활성 효과의 경우 3번의 반복된 실험에서 실험의 오차가 많이 나서 뚜렷 한 경향을 보이는 균주는 보이지 않았으나 125-3, 198-2, P11-3에서 효과가 있는 것으로 나타났다(이하 표 4 참조). In the case of immune activity effect, three repeated experiments resulted in a lot of error of experiments, but no obvious tendency was observed in strains, but it was shown to be effective in 125-3, 198-2, P11-3 (see Table 4 below).
[표 4] 균주를 처리한 대식세포에서의 NO 생성 정도[Table 4] NO production in macrophages treated with the strain
<실험예 3> 항염증활성 효과에 관한 실험Experimental Example 3 Experiment on Anti-inflammatory Activity
1. 항염증활성 효과 측정방법1. How to measure anti-inflammatory activity
상시 실시예에 의하여 1차 선발된 균주의 항염증 효과를 보기 위하여 대식 세포인 RAW 264.7 세포주에 염증 유발 인자인 LPS를 처리하고, 여기에 균 시료 10% 희석액을 처리한 다음 20시간 배양하였다. 배양이 끝난 후 사용한 배지를 이용해 여기에 포함되어 있는 NO의 양을 Griess 시약을 이용하여 측정하였다. In order to see the anti-inflammatory effect of the first-selected strain according to the usual example, macrophage RAW 264.7 cell line was treated with LPS, an inflammation-inducing factor, and treated with 10% dilution of the bacterial sample, followed by incubation for 20 hours. After incubation, the amount of NO contained in the medium was measured using Griess reagent.
2. 항염증활성 효과 측정결과2. Measurement result of anti-inflammatory activity
20개 1차 선발균주의 항염증 효과 측정결과 124-2가 NO의 과발현을 가장 많이 억제 하는 것으로 나타났으며, 이외에도 P11-4, 128-4, 111-5, 125-3, 148-2, 198-2, 197-4 등에서도 효과가 높게 나타났다(도 1 참조). As a result of measuring the anti-inflammatory effect of 20 primary screening strains, 124-2 suppressed the overexpression of NO. In addition, P11-4, 128-4, 111-5, 125-3, 148-2, The effect was also high in 198-2, 197-4, etc. (refer FIG. 1).
<실험예 4> 2차 선발된 균주의 효과에 관한 실험Experimental Example 4 Experiments on the Effects of Secondarily Selected Strains
1. 20개의 1차 선발균주를 이용한 항암활성 (MTT assay). 면역활성 및 항염증 활성 실험결과를 바탕으로 최종적으로 세 균주 (148-2, 197-4, 284-2)를 2차 선발하였고, 이들 3개의 2차 선발균주를 이용하여 추가적인 건강기능활성 측정 실험을 수행하였다. 추가적인 건강 기능활성 측정 실험에서는 균주들이 분비하는 물질과 균주의 세포독성을 별도로 보기위해 물질을 균과 분리하여 활성을 측정하였으며, 해독효소계의 활성효과를 보기위해 QR (Quinone reductase)활성을 측정하였고, 항산화 정도를 측정하기 위해서 ORAC assay를 이용해 전자 소거능을 측정하였다.1. Anticancer activity using 20 primary selection strains (MTT assay). Finally, three strains (148-2, 197-4, and 284-2) were selected for the second time based on the results of immunological and anti-inflammatory activity experiments. Was performed. In an additional activity test, the activity was measured by separating the substance from the bacteria to see the cytotoxicity of the strain and the substances secreted by the strain. In order to measure the degree of antioxidant, the electronic scavenging ability was measured using ORAC assay.
2. 세포 생장 억제율 측정 2. Measurement of cell growth inhibition rate
먼저 2차 선발균주 (148-2, 197-4, 284-2)를 이용하여 이들이 생성하는 분비물질과 균주자체를 분리시켜 이들의 세포 생장억제율을 측정한 결과는 도 2에서 보여주는 것과 같았다. First, the secretion material produced by the secondary selection strains (148-2, 197-4, and 284-2) and the strains were separated and their cell growth inhibition rate was measured as shown in FIG. 2.
그 결과 전체적으로 생장 억제율은 30% 내외를 보였으며, 3가지 모든 균주에서 균주 자체에 의한 생장 억제율이 분비물질에 의한 것보다 높은 것으로 나타났고, 148-2 균주가 가장 높은 암 세포주 생장 억제율을 보여주고 있음을 알 수 있다(도 2 참조).As a result, the overall growth inhibition rate was about 30%. In all three strains, the growth inhibition rate by the strain itself was higher than that by the secretory substance, and 148-2 strain showed the highest growth inhibition rate of cancer cell line. It can be seen that there is (see Fig. 2).
3. QR(quinone reductase)활성 측정3. Measurement of QR (quinone reductase) activity
2차 선발균주 (148-2, 197-4, 284-2)를 이용하여 간암세포주인 Hepa1c1c7를 이용한 무독화 효소들 중의 하나인 QR(quinone reductase) 활성을 측정한 결과는 도 3에서 보여주는 것과 같았다. As a result of measuring the quinone reductase (QR) activity, which is one of detoxification enzymes using hepa1c1c7, a liver cancer cell line, using secondary selection strains (148-2, 197-4, and 284-2) was shown in FIG. .
간암세포주인 Hepa1c1c7을 배양하여 10%의 균주시료 희석액을 처리하고 24시간 동안 배양한 후 세포를 회수하여 QR(quinone reductase) 활성을 측정한 결과, 3가지 선발균주 모두에서 QR 활성이 대조군에 비해 높은 것으로 나타났으며, 148-2 균주의 QR 활성이 높은 것으로 나타났다(도 3 참조).Hepa1c1c7, a hepatocellular carcinoma cell line, was treated with 10% strain sample dilution solution and cultured for 24 hours, and then the cells were recovered to measure QR (quinone reductase) activity.The QR activity was higher in all three selected strains than the control group. It was found that the QR activity of the 148-2 strain was high (see FIG. 3).
4. 항산화활성 측정 4. Antioxidant Activity
2차 선발균주 (148-2, 197-4, 284-2)를 이용한 항산화 효과 측정 결과는 도 4 및 도 5에서 보여주는 것과 같았다. Antioxidant effect measurement results using the second selection strain (148-2, 197-4, 284-2) were as shown in Figures 4 and 5.
세 가지 모든 균주가 peroxyl radical과 hydroxy radical 소거활성을 가지는 것으로 나타났고 hydroxyl radical의 경우에 148-2 균주의 항산화활성이 다른 균주보다 우수한 것으로 나타났다(도 4 및 5 참조).All three strains were found to have peroxyl radical and hydroxy radical scavenging activity, and in the case of hydroxyl radical, the antioxidant activity of 148-2 strain was superior to other strains (see FIGS. 4 and 5).
5. 균주의 동정과 염기서열 분석5. Identification and Sequencing of Strains
1) 위의 결과를 종합했을 때 3개의 2차 선발균주 중 148-2 균주가 건강기능활성 효과가 가장 뛰어난 것으로 나타났으며, 이를 바탕으로 우리는 최종적으로 148-2 균주를 선발하게 되었다. 1) Based on the above results, 148-2 strains out of the three secondary selection strains showed the best health functional effects. Based on this, we finally selected 148-2 strains.
2) 상기 1)의 선발된 균주를 16S rRNA 염기서열 분석을 통해 동정을 하였으며, 동정 결과 148-2 균주는 와이셀라 시바리아(Weisella cibaria)인 균종으로 밝혀졌으며, 균주 동정 결과 와이셀라 시바리아(Weisella cibaria)와 99% 정도의 상동성을 나타내어, 와이셀라 시바리아(Weisella cibaria) 148-2 균주로 명명하였으며, 상기 와이셀라 시바리아 148-2 균주는 농업생명공학연구원에 2008년 12월 9일 미생물 수탁번호 KACC 91421P로 기탁을 하였다. 와이셀라 시바리아 148-2 균주의 16S rRNA 염기서열 분석결과는 이하 표 5에서 보여주는 것과 같았다(이하 표 5 참조).2) The selected strain of 1) was identified by 16S rRNA sequencing analysis. As a result, 148-2 strains were identified as the species of Weisella cibaria . Weisella cibaria ) and about 99% homology, was named as Weisella cibaria 148-2 strain, the strain was named Weisella cibaria 148-2 9 December 2008 It was deposited with the microbial accession number KACC 91421P. 16S rRNA sequencing results of the wine cellar Sibaria 148-2 strain were as shown in Table 5 below (see Table 5 below).
[표 5] Weisella cibaria 148-2 균주의 염기서열Table 5 Sequences of Weisella cibaria 148-2 Strains
61 TGATTTGAAG AGCTTGCTCA GATATGACGA TGGACATTGC AAAGAGTGGC GAACGGGTGA61 TGATTTGAAG AGCTTGCTCA GATATGACGA TGGACATTGC AAAGAGTGGC GAACGGGTGA
121 GTAACACGTG GGAAACCTAC CTCTTAGCAG GGGATAACAT TTGGAAACAG ATGCTAATAC121 GTAACACGTG GGAAACCTAC CTCTTAGCAG GGGATAACAT TTGGAAACAG ATGCTAATAC
181 CGTATAACAA TAGCAACCGC ATGGTTGCTA CTTAAAAGAT GGTTCTGCTA TCACTAAGAG181 CGTATAACAA TAGCAACCGC ATGGTTGCTA CTTAAAAGAT GGTTCTGCTA TCACTAAGAG
241 ATGGTCCCGC GGTGCATTAG TTAGTTGGTG AGGTAATGGC TCACCAAGAC GATGATGCAT241 ATGGTCCCGC GGTGCATTAG TTAGTTGGTG AGGTAATGGC TCACCAAGAC GATGATGCAT
301 AGCCGAGTTG AGAGACTGAT CGGCCACAAT GGGACTGAGA CACGGCCCAT ACTCCTACGG301 AGCCGAGTTG AGAGACTGAT CGGCCACAAT GGGACTGAGA CACGGCCCAT ACTCCTACGG
361 GAGGCAGCAG TAGGGAATCT TCCACAATGG GCGAAAGCCT GATGGAGCAA CGCCGCGTGT361 GAGGCAGCAG TAGGGAATCT TCCACAATGG GCGAAAGCCT GATGGAGCAA CGCCGCGTGT
421 GTGATGAAGG GTTTCGGCTC GTAAAACACT GTTGTAAGAG AAGAATGACA TTGAGAGTAA421 GTGATGAAGG GTTTCGGCTC GTAAAACACT GTTGTAAGAG AAGAATGACA TTGAGAGTAA
481 CTGTTCAATG TGTGACGGTA TCTTACCAGA AAGGAACGGC TAAATACGTG CCAGCAGCCG481 CTGTTCAATG TGTGACGGTA TCTTACCAGA AAGGAACGGC TAAATACGTG CCAGCAGCCG
541 CGGTAATACG TATGTTCCAA GCGTTATCCG GATTTATTGG GCGTAAAGCG AGCGCAGACG541 CGGTAATACG TATGTTCCAA GCGTTATCCG GATTTATTGG GCGTAAAGCG AGCGCAGACG
601 GTTATTTAAG TCTGAAGTGA AAGCCCTCAG CTCAACTGAG GAATTGCTTT GGAAACTGGA601 GTTATTTAAG TCTGAAGTGA AAGCCCTCAG CTCAACTGAG GAATTGCTTT GGAAACTGGA
661 TGACTTGAGT GCAGTAGAGG AAAGTGGAAC TCCATGTGTA GCGGTGAAAT GCGTAGATAT661 TGACTTGAGT GCAGTAGAGG AAAGTGGAAC TCCATGTGTA GCGGTGAAAT GCGTAGATAT
721 ATGGAAGAAC ACCAGTGGCG AAGGCGGCTT TCTGGACTGT AACTGACGTT GAGGCTCGAA721 ATGGAAGAAC ACCAGTGGCG AAGGCGGCTT TCTGGACTGT AACTGACGTT GAGGCTCGAA
781 AGTGTGGGTA GCAAACAGGA TTAGATACCC TGGTAGTCCA CACCGTAAAC GATGAGTGCT781 AGTGTGGGTA GCAAACAGGA TTAGATACCC TGGTAGTCCA CACCGTAAAC GATGAGTGCT
841 AGGTGTTTGA GGGTTTCCGC CCTTAAGTGC CGCAGCTAAC GCATTAAGCA CTCCGCCTGG841 AGGTGTTTGA GGGTTTCCGC CCTTAAGTGC CGCAGCTAAC GCATTAAGCA CTCCGCCTGG
901 GGAGTACGAC CGCAAGGTTG AAACTCAAAG GAATTGACGG GGACCCGCAC AAGCGGTGGA901 GGAGTACGAC CGCAAGGTTG AAACTCAAAG GAATTGACGG GGACCCGCAC AAGCGGTGGA
961 GCATGTGGTT TAATTCGAAG CAACGCGAAG AACCTTACCA GGTCTTGACA TCCCTTGACA961 GCATGTGGTT TAATTCGAAG CAACGCGAAG AACCTTACCA GGTCTTGACA TCCCTTGACA
1021 ACTCCAGAGA TGGAGCGTTC CCTTCGGGGA CAAGGTGACA GGTGGTGCAT GGTTGTCGTC1021 ACTCCAGAGA TGGAGCGTTC CCTTCGGGGA CAAGGTGACA GGTGGTGCAT GGTTGTCGTC
1081 AGCTCGTGTC GTGAGATGTT GGGTTAAGTC CCGCAACGAG CGCAACCCTT ATTACTAGTT1081 AGCTCGTGTC GTGAGATGTT GGGTTAAGTC CCGCAACGAG CGCAACCCTT ATTACTAGTT
1141 GCCAGCATTC AGTTGGGCAC TCTAGTGAGA CTGCCGGTGA CAAACCGGAG GAAGGTGGGG1141 GCCAGCATTC AGTTGGGCAC TCTAGTGAGA CTGCCGGTGA CAAACCGGAG GAAGGTGGGG
1201 ATGACGTCAA ATCATCATGC CCCTTATGAC CTGGGCTACA CACGTGCTAC AATGGCGTAT1201 ATGACGTCAA ATCATCATGC CCCTTATGAC CTGGGCTACA CACGTGCTAC AATGGCGTAT
1261 ACAACGAGTT GCCAACCCGC GAGGGTGAGC TAATCTCTTA AAGTACGTCT CAGTTCGGAT1261 ACAACGAGTT GCCAACCCGC GAGGGTGAGC TAATCTCTTA AAGTACGTCT CAGTTCGGAT
1321 TGTAGGCTGC AACTCGCCTA CATGAAGTCG GAATCGCTAG TAATCGCGGA TCAGCACGCC1321 TGTAGGCTGC AACTCGCCTA CATGAAGTCG GAATCGCTAG TAATCGCGGA TCAGCACGCC
1381 GCGGGTGAAT ACGTTCCCGG GTCTTGTACA CACCGCCCGT CACACCATGA 1381 GCGGGTGAAT ACGTTCCCGG GTCTTGTACA CACCGCCCGT CACACCATGA
<실험예 5> 막걸리에 첨가한 와이셀라 시바리아 148-2 균주에 관한 효과 실험Experimental Example 5 Wiseella Sibaria Added to Makgeolli Effect experiment on 148-2 strain
최종적으로 선발된 와이셀라 시바리아 148-2 균주를 막걸리에 첨가했을 때 균주가 건강 기능활성에 미치는 영향을 보기 위해서 살균된 시판 막걸리에 와이셀라 시바리아 148-2 균주를 첨가하고 일주일 동안 5℃에 보관한 다음 이들의 세포 생장 억제율을 확인하였다. In order to see the effect of strains on wine health, the selected strains of Waisella Sibaria 148-2 were added to makgeolli. After storage, their cell growth inhibition rate was confirmed.
대장암 세포주인 SNU-C4를 이용해서 72시간 동안 처리하고 생장 억제율을 측정한 결과, 균주를 첨가하지 않은 막걸리보다 균주를 첨가한 막걸리에서 세포의 생장 억제율이 증가된 것을 확인할 수 있었다(도 6 참조). Treatment for 72 hours using SNU-C4, a colorectal cancer cell line, and growth inhibition rate were measured. As a result, the growth inhibition rate of the cells was increased in the rice wine with strains rather than the rice wine without strains (see FIG. 6). ).
본 발명의 젖산균주는 건강에 좋은 발효주의 스타터가 되어 기능성을 가지는 전통주를 제공하여 일반 수요자의 욕구과 건전한 음주문화 형성에 이바지 하며, 생산자의 이윤창출 및 수출촉진에도 기여하여, 궁극적으로 국가의 산업발전에 공헌 할 것으로 기대된다.Lactobacillus strain of the present invention serves as a starter of healthy fermented liquor, providing traditional liquor having functionality, contributing to the needs of general consumers and forming a healthy drinking culture, contributing to the profit creation and export promotion of producers, ultimately to the industrial development of the country It is expected to contribute.
도 1은 LPS(염증유발인자)로 자극된 RAW 264.7 세포주에서의 NO 생성 억제 정도를 나타낸다(vehicle은 세포주에 아무것도 첨가하지 않은 경우이다.). Figure 1 shows the degree of NO production inhibition in RAW 264.7 cell line stimulated with LPS (inflammatory trigger) (vehicle when nothing is added to the cell line).
도 2는 균주와 균주가 생성한 물질의 세포독성을 나타낸다(total은 균주와 균주가 생성한 분비물질 전체를 말하는 것이고, pellet은 균주 자체, supernatant는 균주가 생성한 분비물질을 나타내는 것이다.). Figure 2 shows the cytotoxicity of the strain and the material produced by the strain (total refers to the total secretion produced by the strain and strain, pellet refers to the strain itself, supernatant refers to the secreted material produced by the strain).
도 3은 균주의 QR(Quinone reductase) 활성화를 나타낸다(vehicle은 세포주에 아무것도 첨가하지 않은 경우이다.).Figure 3 shows the QR (Quinone reductase) activation of the strain (vehicle is when nothing is added to the cell line).
도 4는 균주의 항산화 작용으로, 페록시 라디컬(Peroxyl radical) 소거능을 나타낸다(도 왼쪽상단의 농도는 균주가 자란 배지를 100%로 보았을때, 실험에 사용된 농도이다.).Figure 4 shows the antioxidant activity of the strain, showing the peroxyl radical (Peroxyl radical) scavenging ability (concentration in the upper left is the concentration used in the experiment, when the strain was grown to 100% medium).
도 5는 균주의 항산화 작용으로, 히드록시 라디컬(Hydroxyl radical) 소거능을 나타낸다(도 왼쪽상단의 농도는 균주가 자란 배지를 100%로 보았을때, 실험에 사용된 농도이다.). Figure 5 shows the antioxidant activity of the strain, showing the hydroxy radical (Hydroxyl radical) scavenging ability (concentration in the upper left of the Figure is the concentration used in the experiment, when viewing the culture medium grown
도 6은 막걸리에 첨가한 와이셀라 시바리아(Weisella cibaria) 148-2 균주의 세포 생장 억제율을 나타낸다.Figure 6 is Weisella cibaria added to the rice wine It shows the rate of cell growth inhibition of 148-2 strain.
<110> korea food research lnstitute <120> Weissella cibaria 148-2 lactic bacteria for functional healthy effect and Makgeolli containing the same <160> 1 <170> KopatentIn 1.71 <210> 1 <211> 1430 <212> DNA <213> Weisella cibaria 148-2 <400> 1 ctcaggatga acgctggcgg cgtgcctaat acatgcaagt cgaacgcttt gtggttcaac 60 tgatttgaag agcttgctca gatatgacga tggacattgc aaagagtggc gaacgggtga 120 gtaacacgtg ggaaacctac ctcttagcag gggataacat ttggaaacag atgctaatac 180 cgtataacaa tagcaaccgc atggttgcta cttaaaagat ggttctgcta tcactaagag 240 atggtcccgc ggtgcattag ttagttggtg aggtaatggc tcaccaagac gatgatgcat 300 agccgagttg agagactgat cggccacaat gggactgaga cacggcccat actcctacgg 360 gaggcagcag tagggaatct tccacaatgg gcgaaagcct gatggagcaa cgccgcgtgt 420 gtgatgaagg gtttcggctc gtaaaacact gttgtaagag aagaatgaca ttgagagtaa 480 ctgttcaatg tgtgacggta tcttaccaga aaggaacggc taaatacgtg ccagcagccg 540 cggtaatacg tatgttccaa gcgttatccg gatttattgg gcgtaaagcg agcgcagacg 600 gttatttaag tctgaagtga aagccctcag ctcaactgag gaattgcttt ggaaactgga 660 tgacttgagt gcagtagagg aaagtggaac tccatgtgta gcggtgaaat gcgtagatat 720 atggaagaac accagtggcg aaggcggctt tctggactgt aactgacgtt gaggctcgaa 780 agtgtgggta gcaaacagga ttagataccc tggtagtcca caccgtaaac gatgagtgct 840 aggtgtttga gggtttccgc ccttaagtgc cgcagctaac gcattaagca ctccgcctgg 900 ggagtacgac cgcaaggttg aaactcaaag gaattgacgg ggacccgcac aagcggtgga 960 gcatgtggtt taattcgaag caacgcgaag aaccttacca ggtcttgaca tcccttgaca 1020 actccagaga tggagcgttc ccttcgggga caaggtgaca ggtggtgcat ggttgtcgtc 1080 agctcgtgtc gtgagatgtt gggttaagtc ccgcaacgag cgcaaccctt attactagtt 1140 gccagcattc agttgggcac tctagtgaga ctgccggtga caaaccggag gaaggtgggg 1200 atgacgtcaa atcatcatgc cccttatgac ctgggctaca cacgtgctac aatggcgtat 1260 acaacgagtt gccaacccgc gagggtgagc taatctctta aagtacgtct cagttcggat 1320 tgtaggctgc aactcgccta catgaagtcg gaatcgctag taatcgcgga tcagcacgcc 1380 gcgggtgaat acgttcccgg gtcttgtaca caccgcccgt cacaccatga 1430 <110> korea food research lnstitute <120> Weissella cibaria 148-2 lactic bacteria for functional healthy effect and Makgeolli containing the same <160> 1 <170> KopatentIn 1.71 <210> 1 <211> 1430 <212> DNA <213> Weisella cibaria 148-2 <400> 1 ctcaggatga acgctggcgg cgtgcctaat acatgcaagt cgaacgcttt gtggttcaac 60 tgatttgaag agcttgctca gatatgacga tggacattgc aaagagtggc gaacgggtga 120 gtaacacgtg ggaaacctac ctcttagcag gggataacat ttggaaacag atgctaatac 180 cgtataacaa tagcaaccgc atggttgcta cttaaaagat ggttctgcta tcactaagag 240 atggtcccgc ggtgcattag ttagttggtg aggtaatggc tcaccaagac gatgatgcat 300 agccgagttg agagactgat cggccacaat gggactgaga cacggcccat actcctacgg 360 gaggcagcag tagggaatct tccacaatgg gcgaaagcct gatggagcaa cgccgcgtgt 420 gtgatgaagg gtttcggctc gtaaaacact gttgtaagag aagaatgaca ttgagagtaa 480 ctgttcaatg tgtgacggta tcttaccaga aaggaacggc taaatacgtg ccagcagccg 540 cggtaatacg tatgttccaa gcgttatccg gatttattgg gcgtaaagcg agcgcagacg 600 gttatttaag tctgaagtga aagccctcag ctcaactgag gaattgcttt ggaaactgga 660 tgacttgagt gcagtagagg aaagtggaac tccatgtgta gcggtgaaat gcgtagatat 720 atggaagaac accagtggcg aaggcggctt tctggactgt aactgacgtt gaggctcgaa 780 agtgtgggta gcaaacagga ttagataccc tggtagtcca caccgtaaac gatgagtgct 840 aggtgtttga gggtttccgc ccttaagtgc cgcagctaac gcattaagca ctccgcctgg 900 ggagtacgac cgcaaggttg aaactcaaag gaattgacgg ggacccgcac aagcggtgga 960 gcatgtggtt taattcgaag caacgcgaag aaccttacca ggtcttgaca tcccttgaca 1020 actccagaga tggagcgttc ccttcgggga caaggtgaca ggtggtgcat ggttgtcgtc 1080 agctcgtgtc gtgagatgtt gggttaagtc ccgcaacgag cgcaaccctt attactagtt 1140 gccagcattc agttgggcac tctagtgaga ctgccggtga caaaccggag gaaggtgggg 1200 atgacgtcaa atcatcatgc cccttatgac ctgggctaca cacgtgctac aatggcgtat 1260 acaacgagtt gccaacccgc gagggtgagc taatctctta aagtacgtct cagttcggat 1320 tgtaggctgc aactcgccta catgaagtcg gaatcgctag taatcgcgga tcagcacgcc 1380 gcgggtgaat acgttcccgg gtcttgtaca caccgcccgt cacaccatga 1430
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080133488A KR101014317B1 (en) | 2008-12-24 | 2008-12-24 | Weissella cibaria 148-2 lactic bacteria for functional healthy effect and Makgeolli containing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080133488A KR101014317B1 (en) | 2008-12-24 | 2008-12-24 | Weissella cibaria 148-2 lactic bacteria for functional healthy effect and Makgeolli containing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100074928A KR20100074928A (en) | 2010-07-02 |
KR101014317B1 true KR101014317B1 (en) | 2011-02-14 |
Family
ID=42637399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080133488A KR101014317B1 (en) | 2008-12-24 | 2008-12-24 | Weissella cibaria 148-2 lactic bacteria for functional healthy effect and Makgeolli containing the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101014317B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101424612B1 (en) | 2012-06-08 | 2014-08-06 | 주식회사 국순당 | Weisella cibaria ksd-914 having acid-resistance and anti-bile |
KR101536672B1 (en) * | 2013-09-17 | 2015-07-24 | 충북대학교 산학협력단 | Novel Weissella cibaria JW15 strain and use the same |
KR20210108781A (en) * | 2020-02-26 | 2021-09-03 | 경일대학교산학협력단 | Weissella cibaria JSKIU 18-18 (KCTC18806P) from fermented local food in Jeju and composition with the function of anti-aging, anti-cancer and anti-dental caries thereof |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101453853B1 (en) * | 2013-03-04 | 2014-10-29 | 주식회사 국순당 | Preparation method of lactic acid bacteria-containg rice wine which has high content of probiotics lactic bacteria and improved stability |
KR101667496B1 (en) * | 2015-10-15 | 2016-10-18 | 한국식품연구원 | Pharmaceutical composition for prevention or treatment of atopic dermatitis comprising Weissella cibaria WIKIM28 as active ingredient |
KR20180054029A (en) * | 2016-11-14 | 2018-05-24 | 전북대학교산학협력단 | Composition for improving immunity comprising exopolysaccharide derived from Weissella cibaria |
KR102009742B1 (en) * | 2018-12-10 | 2019-08-12 | 한국식품연구원 | Pharmaceutical composition for prevention or treatment of cancer comprising Weissella cibaria WIKIM28 as active ingredient |
KR102356626B1 (en) * | 2018-12-10 | 2022-01-28 | 주식회사 엠디헬스케어 | Nanovesicles derived from Weissella bacteria and Use thereof |
JP7240031B2 (en) * | 2018-12-10 | 2023-03-15 | エムディー ヘルスケア インコーポレイテッド | Nanovesicles derived from Weissella bacteria and uses thereof |
US20230346857A1 (en) * | 2020-01-31 | 2023-11-02 | Liscure Biosciences Co., Ltd. | Pharmaceutical composition for prevention or treatment of cancer comprising weissella cibaria wikim28 as active ingredient |
WO2022145900A1 (en) * | 2020-12-28 | 2022-07-07 | 주식회사 리스큐어바이오사이언시스 | Pharmaceutical composition for preventing or treating cancer, comprising as active ingredient nanovesicles derived from weissella cibaria strain |
WO2022177411A1 (en) * | 2021-02-22 | 2022-08-25 | 주식회사 리스큐어바이오사이언시스 | Pharmaceutical composition for prevention or treatment of cancer comprising weissella cibaria lbml2 strain as active ingredient |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070009503A1 (en) | 2004-12-17 | 2007-01-11 | Akinori Uehara | Antibiotic, Compositions Containing the Antibiotic, and Methods for Administering the Antibiotic and/or Said Compositions to Livestock |
-
2008
- 2008-12-24 KR KR1020080133488A patent/KR101014317B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070009503A1 (en) | 2004-12-17 | 2007-01-11 | Akinori Uehara | Antibiotic, Compositions Containing the Antibiotic, and Methods for Administering the Antibiotic and/or Said Compositions to Livestock |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101424612B1 (en) | 2012-06-08 | 2014-08-06 | 주식회사 국순당 | Weisella cibaria ksd-914 having acid-resistance and anti-bile |
KR101536672B1 (en) * | 2013-09-17 | 2015-07-24 | 충북대학교 산학협력단 | Novel Weissella cibaria JW15 strain and use the same |
KR20210108781A (en) * | 2020-02-26 | 2021-09-03 | 경일대학교산학협력단 | Weissella cibaria JSKIU 18-18 (KCTC18806P) from fermented local food in Jeju and composition with the function of anti-aging, anti-cancer and anti-dental caries thereof |
KR102330010B1 (en) | 2020-02-26 | 2021-11-23 | 경일대학교산학협력단 | Weissella cibaria JSKIU 18-18 (KCTC18806P) from fermented local food in Jeju and composition with the function of anti-aging, anti-cancer and anti-dental caries thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20100074928A (en) | 2010-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101014317B1 (en) | Weissella cibaria 148-2 lactic bacteria for functional healthy effect and Makgeolli containing the same | |
Roger et al. | Nutritional properties and antinutritional factors of corn paste (Kutukutu) fermented by different strains of lactic acid bacteria | |
KR102000475B1 (en) | Bacillus amyloliquefaciens NY12-2 strain having antibiotic activity against Bacillus cereus and inhibitory activity on biogenic amine and compositions thereof | |
CN107158040B (en) | Oral micro-ecological preparation and preparation method thereof | |
Grosu-Tudor et al. | Microbial and nutritional characteristics of fermented wheat bran in traditional Romanian borş production | |
KR101482068B1 (en) | Method for producing low-salt soy sauce using yeast strains from traditionally fermented soybean products | |
KR101451810B1 (en) | Novel Strains of Lactobacillus plantarum K255 with High Productivity of Gamma-Aminobutyric Acid | |
KR100871398B1 (en) | Lactobacillus buchneri OPY-2 and fermented milk containing thereof | |
KR20210106930A (en) | Lactobacillus plantarum KCC-24 and composition comprising the same | |
CN111480729B (en) | Synergistic fermentation method of bacterial enzymes containing rapeseed meal | |
KR102184119B1 (en) | Novel strain Saccharomyces cerevisiae EY2-27 having skin whitening and use of the same | |
KRABI et al. | Screening of lactic acid bacteria as potential starter for the production of ATTIEKE, a fermented cassava food | |
KR102542030B1 (en) | Makgeolli-derived Lacticaseibacillus paracasei subsp. paracasei DCF0429 and functional postbiotics using the same | |
KR20150125836A (en) | Lactobacillus plantarum js1 and synbiotics functional makgeolli prepared therewith | |
KR101313120B1 (en) | Manufacturing method of rice Kefir by using Lactobacillus plantarum and Saccharomyces cerevisiae | |
KR101970148B1 (en) | Novel Lactobacillus sakei KR18 with probiotic activities | |
KR101068524B1 (en) | Fermented milk Using Lactobacillus plantarum M23 and Preparation method thereof | |
KR101744529B1 (en) | Bacillus subtilis 1-d-5, method for growth stimulation of bifidobacteria and method for manufacturing of enzyme food using thereof | |
KR102353394B1 (en) | Methods for preparing oat doenjang using a novel Bacillus subtilis TSD | |
KR102184142B1 (en) | Novel strain Wickerhamomyces anomalus EY2-22 having skin whitening and use of the same | |
KR20140022652A (en) | New leuconostoc citreum and food including the same | |
KR101350796B1 (en) | Kazachstania exigua CCSY27 strain having probiotics properties and preparation of makgeolli by using the strain | |
Adisa et al. | Microbiological and probiotic assessment of yeast isolated from wholegrain millet sourdoughs | |
KR101859679B1 (en) | The acid, sugar and alcohol resistance lactic acid bacteria | |
TWI822167B (en) | Oolong tea ferment, method of preparing the same, food composition including the same and its use for manufacturing food composition with anti-oxidative effect and angiotensin converting enzyme inhibiting effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140210 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150204 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160212 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170102 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20190408 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20200102 Year of fee payment: 10 |
|
R401 | Registration of restoration |